Dephosphorylation of AMP-activated Protein Kinase Exacerbates Ischemia/reperfusion-induced Acute Kidney Injury Via Mitochondrial Dysfunction
Overview
Authors
Affiliations
Kidney tubular epithelial cells are high energy-consuming epithelial cells that depend mainly on fatty acid oxidation for an energy supply. AMP-activated protein kinase (AMPK) is a key regulator of energy production in most cells, but the function of AMPK in tubular epithelial cells in acute kidney disease is unclear. Here, we found a rapid decrease in Thr172-AMPKα phosphorylation after ischemia/reperfusion in both in vivo and in vitro models. Mice with kidney tubular epithelial cell-specific AMPKα deletion exhibited exacerbated kidney impairment and apoptosis of tubular epithelial cells after ischemia/reperfusion. AMPKα deficiency was accompanied by the accumulation of lipid droplets in the kidney tubules and the elevation of ceramides and free fatty acid levels following ischemia/reperfusion injury. Mechanistically, ischemia/reperfusion triggered ceramide production and activated protein phosphatase PP2A, which dephosphorylated Thr172-AMPKα. Decreased AMPK activity repressed serine/threonine kinase ULK1-mediated autophagy and impeded clearance of the dysfunctional mitochondria. Targeting the PP2A-AMPK axis by the allosteric AMPK activator C24 restored fatty acid oxidation and reduced tubular cell apoptosis during ischemia/reperfusion-induced injury, by antagonizing PP2A dephosphorylation and promoting the mitophagy process. Thus, our study reveals that AMPKα plays an important role in protecting against tubular epithelial cell injury in ischemia/reperfusion-induced acute kidney injury. Hence, activation of AMPK could be a potential therapeutic strategy for acute kidney injury treatment.
Annexin A's Life in Pan-Cancer: Especially in Glioma Immune Cells.
Wen Y, Zhou W, Zhao Z, Ma D, Mao J, Cai Y Neuromolecular Med. 2025; 27(1):17.
PMID: 40011350 DOI: 10.1007/s12017-024-08827-9.
Sun Y, Li B, Song B, Xia Y, Ye Z, Lin F Cell Biol Toxicol. 2025; 41(1):39.
PMID: 39899077 PMC: 11790803. DOI: 10.1007/s10565-025-09991-9.
Lipidomics-based natural products for chronic kidney disease treatment.
Zhang R, Wang J, Wu C, Wang L, Liu P, Li P Heliyon. 2025; 11(1):e41620.
PMID: 39866478 PMC: 11758422. DOI: 10.1016/j.heliyon.2024.e41620.
Lyon A, Agius T, MacArthur M, Kiesworo K, Stavart L, Allagnat F iScience. 2025; 27(12):111256.
PMID: 39759002 PMC: 11700642. DOI: 10.1016/j.isci.2024.111256.
Li X, Chen J, Li J, Zhang Y, Xia J, Du H Mol Ther. 2025; 33(2):805-822.
PMID: 39748508 PMC: 11853023. DOI: 10.1016/j.ymthe.2024.12.053.